Senaste försöken

EudraCT Number: 2022-004078-53

Sponsor Protocol Number: 83403

Start Date: 2023-08-22

Sponsor Name: Academic Medical Center (AMC), department of Internal Medicine

Full Title: Specifying the anti-inflammatory effects of ziltivekimab with diverse imaging modalities and in-depth cellular phenotyping

Medical condition: - Plaque characteristics - Systemic inflammation

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002788-30

Sponsor Protocol Number: IMVT-1401-3202

Start Date: 2023-07-13

Sponsor Name: Immunovant Sciences, GmbH

Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)

Medical condition: Thyroid Eye Disease (TED)

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.1	100000004853	10084358	Thyroid eye disease	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) BE (Ongoing) LV (Ongoing) HU (Ongoing) SK (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003584-18

Sponsor Protocol Number: KKS-307

Start Date: 2023-06-26

Sponsor Name: Philipps University Marburg

Full Title: Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia

Medical condition: Progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10038738 - Respiratory, thoracic and mediastinal disorders	10021240	Idiopathic pulmonary fibrosis	PT
	21.1	10038738 - Respiratory, thoracic and mediastinal disorders	10022619	Interstitial pulmonary fibrosis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000430-42

Sponsor Protocol Number: 67953964MDD3003_VENTURA-LT

Start Date: 2023-06-22

Sponsor Name: Janssen-Cilag International NV

Full Title: An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)

Medical condition: Major Depressive Disorder (MDD)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004873	10025453	Major depressive disorder NOS	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Ongoing) HU (Ongoing) CZ (Ongoing) PL (Ongoing) BG (Ongoing) ES (Ongoing) PT (Ongoing) SK (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000692-39

Sponsor Protocol Number: IVY

Start Date: 2023-06-19

Sponsor Name: Amsterdam University Medical Center

Full Title: Safety, tolerability and immunogenicity of intradermal mRNA SARS-CoV2 vaccination in patients with Fibrodysplasia Ossificans Progressiva

Medical condition: Fibrodyplasia Ossificans Progressiva (FOP)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10068715	Fibrodysplasia ossificans progressiva	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003594-33

Sponsor Protocol Number: EORTC-1984-BCG

Start Date: 2023-06-16

Sponsor Name: European Organisation for Research and Treatment of Cancer (EORTC)

Full Title: Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer (NOBLE)

Medical condition: Triple negative breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10075566	Triple negative breast cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000690-73

Sponsor Protocol Number: BAY86-5321/21912

Start Date: 2023-06-06

Sponsor Name: Bayer AG

Full Title: A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive customized Treatment Intervals in Patients ≥50 Years of Age wi...

Medical condition: Neovascular (wet) age-related macular degeneration

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10015919 - Eye disorders	10071129	Neovascular age-related macular degeneration	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000054-28

Sponsor Protocol Number: OLIGOTREAT

Start Date: 2023-06-02

Sponsor Name: Klinikum der Universität München

Full Title: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat)

Medical condition: Schizophrenia

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10037175 - Psychiatric disorders	10039626	Schizophrenia	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002407-37

Sponsor Protocol Number: BET-PSMA-121

Start Date: 2023-05-22

Sponsor Name: Blue Earth Therapeutics Limited

Full Title: An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with met...

Medical condition: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004864	10076506	Castration-resistant prostate cancer	LLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003398-51

Sponsor Protocol Number: R-Pola-Glo

Start Date: 2023-05-16

Sponsor Name: Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest

Full Title: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in...

Medical condition: aggressive large B-cell lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004851	10012819	Diffuse large B-cell lymphomas	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

Senaste försöken

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner